Molecular pathways differentiate hepatitis C virus (HCV) recurrence from acute cellular rejection in HCV liver recipients

Molecular Medicine

Volumn 17, Issue 7-8, 2011, Pages 824-833

  Gehrau, Ricardo ^a   Maluf, Daniel ^a   Archer, Kellie ^b   Stravitz, Richard ^a   Suh, Jihee ^a   Le, Ngoc ^a   Mas, Valeria ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; ARGINASE TYPE 2; CYCLOSPORIN; ETHYLMALONIC ENCEPHALOPATHY 1 PROTEIN; STEROID; TACROLIMUS; TRANSMEMBRANE PROTEIN 176A; UNCLASSIFIED DRUG;

ARG2 GENE; ARTICLE; CLINICAL ASSESSMENT; CLUSTER ANALYSIS; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DRUG WITHDRAWAL; ETHE1 GENE; GENE EXPRESSION; GENE PROBE; GENE SIGNATURE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GRAFT RECIPIENT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LAST ABSOLUTE SHRINKAGE AND SELECTION OPERATOR MODEL; LIVER ALLOGRAFT; LIVER BIOPSY; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MATHEMATICAL ANALYSIS; MICROARRAY ANALYSIS; MOLECULAR PROBE; NUCLEOTIDE SEQUENCE; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENT DISEASE; SENSITIVITY AND SPECIFICITY; TMEM176B GENE; TRAINING; VALIDATION PROCESS;

ACUTE DISEASE; CLUSTER ANALYSIS; DIAGNOSIS, DIFFERENTIAL; GENE EXPRESSION PROFILING; GRAFT REJECTION; HEPATITIS C; HUMANS; LIVER; LIVER TRANSPLANTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POSTOPERATIVE COMPLICATIONS; RECURRENCE; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 79960725837     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2011.00072     Document Type: Article

References (51)

1. Garcia-Retortillo M, et al. (2002) Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology. 35:680-7.
2. Gane EJ, et al. (1996) Long-term outcome of hepatitis C infection after liver transplantation. N. Engl. J. Med. 334:815-20.
3. Roche B, Samuel D. (2007) Risk factors for hepatitis C recurrence after liver transplantation. J. Viral Hepat. 14 Suppl 1:89-96.
4. Demetris AJ. (2009) Evolution of hepatitis C virus in liver allografts. Liver Transpl. 15 Suppl 2:S35-41.
5. Watt K, Veldt B, Charlton M. (2009) A practical guide to the management of HCV infection following liver transplantation. Am. J. Transplant. 9:1707-13.
6. Knechtle SJ, Kwun J. (2009) Unique aspects of rejection and tolerance in liver transplantation. Semin. Liver Dis. 29:91-101.
7. Burton JR Jr, Rosen HR. (2006) Acute rejection in HCV-infected liver transplant recipients: the great conundrum. Liver Transpl. 12:S38-47.
8. Kurian S, et al. (2007) Applying genomics to organ transplantation medicine in both discovery and validation of biomarkers. Int. Immunopharmacol. 7:1948-60.
9. Gelb B, Feng S. (2009) Management of the liver transplant patient. Expert Rev. Gastroenterol. Hepatol. 3:631-47.
10. Manousou P, et al. (2009) Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy. Liver Transpl. 15:1783-91.
11. Demetris AJ, et al. (2004) Recurrent hepatitis C in liver allografts: prospective assessment of diagnostic accuracy, identification of pitfalls, and observations about pathogenesis. Am. J. Surg. Pathol. 28:658-69.
12. Berenguer M, et al. (2003) A model to predict severe HCV-related disease following liver transplantation. Hepatology. 38:34-41.
13. Mas VR, et al. (2006) Differentially expressed genes between early and advanced hepatocellular carcinoma (HCC) as a potential tool for selecting liver transplant recipients. Mol. Med. 12:97-104.
14. Archer KJ, et al. (2009) Identifying genes for establishing a multigenic test for hepatocellular carcinoma surveillance in hepatitis C viruspositive cirrhotic patients. Cancer Epidemiol. Biomarkers Prev. 18:2929-32.
15. Park MY, Hastie T. (2008) Penalized logistic regression for detecting gene interactions. Biostatistics. 9:30-50.
16. R Development Core Team. (2005) R: A Language and Environment for Statistical Computing [computer program]. Vienna (Austria): R Foundation for Statistical Computing. 2011 version available at: http://www.R-project.org.
17. Gentleman RC, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5:R80.
18. Ishibashi M, Wakita T, Esumi M. (2010) 2',5'- Oligoadenylate synthetase-like gene highly induced by hepatitis C virus infection in human liver is inhibitory to viral replication in vitro. Biochem. Biophys. Res. Commun. 392:397-402.
19. Arjona A, Sarkar DK. (2006) The circadian gene mPer2 regulates the daily rhythm of IFN-gamma. J. Interferon Cytokine Res. 26:645-9.
20. Wang M, Windgassen D, Papoutsakis ET. (2008) A global transcriptional view of apoptosis in human T-cell activation. BMC Med. Genomics. 1:53.
21. Higashitsuji H, et al. (2002) A novel protein overexpressed in hepatoma accelerates export of NFkappa B from the nucleus and inhibits p53-dependent apoptosis. Cancer Cell. 2:335-46.
22. Kim MS, Shigenaga J, Moser A, Grunfeld C, Feingold KR. (2004) Suppression of DHEA sulfotransferase (Sult2A1) during the acute-phase response. Am. J. Physiol. Endocrinol. Metab. 287:E731-8.
23. Chen X, Dai JC, Orellana SA, Greenfield EM. (2005) Endogenous protein kinase inhibitor gamma terminates immediate-early gene expression induced by cAMP-dependent protein kinase (PKA) signaling: termination depends on PKA inactivation rather than PKA export from the nucleus. J. Biol. Chem. 280:2700-7.
24. Condamine T, et al. (2010) Tmem176B and Tmem176A are associated with the immature state of dendritic cells. J. Leukoc. Biol. 88:507-15.
25. M. (2007) Regulation of nitric oxide synthesis and apoptosis by arginase and arginine recycling. J. Nutr. 137:1616S-20S.
26. Kenyon NJ, Bratt JM, Linderholm AL, Last MS, Last JA. (2008) Arginases I and II in lungs of ovalbumin-sensitized mice exposed to ovalbumin: sources and consequences. Toxicol. Appl. Pharmacol. 230:269-75.
27. Zimmermann N, et al. (2003) Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J. Clin. Invest. 111:1863-74.
28. De Keyzer D, et al. (2009) Increased PAFAH and oxidized lipids are associated with inflammation and atherosclerosis in hypercholesterolemic pigs. Arterioscler. Thromb. Vasc. Biol. 29:2041-6.
29. Shi Y, et al. (2007) Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses. Atherosclerosis. 191:54-62.
30. Chen R, Yang L, McIntyre TM. (2007) Cytotoxic phospholipid oxidation products: cell death from mitochondrial damage and the intrinsic caspase cascade. J. Biol. Chem. 282:24842-50.
31. John K, Alla V, Meier C, Putzer BM. (2010) GRAMD4 mimics p53 and mediates the apoptotic function of p73 at mitochondria. Cell Death Differ. 18:874-86.
32. Regev A, et al. (2004) Reliability of histopathologic assessment for the differentiation of recurrent hepatitis C from acute rejection after liver transplantation. Liver Transpl. 10:1233-9.
33. D'Errico-Grigioni A, et al. (2008) Tissue hepatitis C virus RNA quantification and protein expression help identify early hepatitis C virus recurrence after liver transplantation. Liver Transpl. 14:313-20.
34. Grassi A, et al. (2006) Detection of HCV antigens in liver graft: relevance to the management of recurrent post-liver transplant hepatitis C. Liver Transpl. 12:1673-81.
35. Unitt E, Gelson W, Davies SE, Coleman N, Alexander GJ. (2009) Minichromosome maintenance protein-2-positive portal tract lymphocytes distinguish acute cellular rejection from hepatitis C virus recurrence after liver transplantation. Liver Transpl. 15:306-12.
36. Jain A, et al. (2006) Characterization of CD4, CD8, CD56 positive lymphocytes and C4d deposits to distinguish acute cellular rejection from recurrent hepatitis C in post-liver transplant biopsies. Clin. Transplant. 20:624-33.
37. Schmeding M, et al. (2006) C4d in acute rejection after liver transplantation: a valuable tool in differential diagnosis to hepatitis C recurrence. Am. J. Transplant. 6:523-30.
38. Schmeding M, et al. (2010) ELISA-based detection of C4d after liver transplantation: a helpful tool for differential diagnosis between acute rejection and HCV-recurrence? Transpl. Immunol. 23:156-60.
39. MacQuillan GC, et al. (2010) Hepatocellular MxA protein expression supports the differentiation of recurrent hepatitis C disease from acute cellular rejection after liver transplantation. Clin. Transplant. 24:252-8.
40. Borgogna C, et al. (2009) Expression of the interferon- inducible proteins MxA and IFI16 in liver allografts. Histopathology. 54:837-46.
41. Cabrera R, et al. (2009) Using an immune functional assay to differentiate acute cellular rejection from recurrent hepatitis C in liver transplant patients. Liver Transpl. 15:216-22.
42. Rubinas T, Dellon E, Henel G. (2009) Use of an immune functional assay to differentiate recurrent hepatitis C from acute cellular rejection in liver transplant patients. Liver Transpl. 15:1157.
43. Hashimoto K, et al. (2010) Measurement of CD4+ T-cell function in predicting allograft rejection and recurrent hepatitis C after liver transplantation. Clin. Transplant. 24:701-8.
44. Maluf DG, Archer KJ, Villamil F, Stravitz RT, Mas V. (2010) Hepatitis C virus recurrence after liver transplantation: biomarkers of disease and fibrosis progression. Expert Rev. Gastroenterol. Hepatol. 4:445-58.
45. Asaoka T, et al. (2009) Differential transcriptome patterns for acute cellular rejection in recipients with recurrent hepatitis C after liver transplantation. Liver Transpl. 15:1738-49.
46. Sreekumar R, Rasmussen DL, Wiesner RH, Charlton MR. (2002) Differential allograft gene expression in acute cellular rejection and recurrence of hepatitis C after liver transplantation. Liver Transpl. 8:814-21.
47. Zekry A, et al. (2002) Intrahepatic cytokine profiles associated with posttransplantation hepatitis C virus-related liver injury. Liver Transpl. 8:292-301.
48. McCaughan GW, Shackel NA, Bertolino P, Bowen DG. (2009) Molecular and cellular aspects of hepatitis C virus reinfection after liver transplantation: how the early phase impacts on outcomes. Transplantation. 87:1105-11.
49. Ramirez S, Perez-Del-Pulgar S, Forns X. (2008) Virology and pathogenesis of hepatitis C virus recurrence. Liver Transpl. 14 Suppl 2:S27-35.
50. Krukemeyer MG, et al. (2004) Description of B lymphocytes and plasma cells, complement, and chemokines/receptors in acute liver allograft rejection. Transplantation. 78:65-70.
51. Ohnmacht C, et al. (2009) Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity. J. Exp. Med. 206:549-59.